Prasugrel REMS: Lilly Proposes MedGuide, FDA Wants More To Mitigate Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly’s proposed REMS consists only of a Medication Guide warning of bleeding risk; FDA suggests the addition of a communication plan regarding the possible cancer risk.
You may also be interested in...
Cancer, Bleeding Risks At The Heart Of Prasugrel Review; Could Limiting Use Help?
FDA discusses labeling to restrict prasugrel use to one week or one month; less frequent dosing regimen would dampen sales projections.
Cancer, Bleeding Risks At The Heart Of Prasugrel Review; Could Limiting Use Help?
FDA discusses labeling to restrict prasugrel use to one week or one month; less frequent dosing regimen would dampen sales projections.
FDA Keen On Lilly’s Prasugrel: Will Advisory Committee Follow Suit?
FDA says that increased risk of bleeding for prasugrel’s clear cardiovascular efficacy is a “reasonable trade.”